Journal of Neuro-Oncology

, 90:341 | Cite as

Low-grade gliomas in older patients: a retrospective analysis of prognostic factors

  • Nader PouratianEmail author
  • Melike Mut
  • Jay Jagannathan
  • M. Beatriz Lopes
  • Mark E. Shaffrey
  • David Schiff
Clinical Study - Patient Study


Low-grade gliomas (LGG) are increasingly being diagnosed in older patients (≥60 years). The rising incidence is incompletely understood but demands an analysis of the natural history and prognostic factors to determine if there are differences compared to younger populations. We retrospectively review a consecutive series of 20 older patients who presented between 1991 and 2004 with LGG to characterize the presentation, management, outcomes, and prognostic factors in older patients with LGG. Median follow-up was 27.3 months. Thirty-five percent of patients harboured oligodendrogliomas. Patients presented in equal numbers with seizure, focal neurological deficit, and mental status change. Median overall survival (OS) was 27.3 months. Patients who survive beyond 2 years experience prolonged periods of progression-free survival. Younger age, seizure presentation, and radiation treatment were prognostic of OS on multivariate analysis. Similarities with previous reports of LGG suggest that age should not affect the management of LGG patients. Prospective studies of older patients with LGG are needed to further characterize the optimum management of these patients.


Low-grade glioma Glioma Elderly Prognosis Risk factors 


  1. 1.
    Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schuler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lutolf UM, Kleihues P, Ohgaki H (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (Berl) 108:49–56CrossRefGoogle Scholar
  2. 2.
    van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C (1998) Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 64:581–587PubMedGoogle Scholar
  3. 3.
    Claus EB, Black PM (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 106:1358–1363PubMedCrossRefGoogle Scholar
  4. 4.
    Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442–1448PubMedGoogle Scholar
  5. 5.
    CBTRUS (2005) Statistical report: Primary Brain Tumors in the United States, 1998–2002. Central Brain Tumor Registry of the United States.
  6. 6.
    Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489PubMedGoogle Scholar
  7. 7.
    Johannesen TB, Angell-Andersen E, Tretli S, Langmark F, Lote K (2004) Trends in incidence of brain and central nervous system tumors in Norway, 1970–1999. Neuroepidemiology 23:101–109PubMedCrossRefGoogle Scholar
  8. 8.
    Lonn S, Klaeboe L, Hall P, Mathiesen T, Auvinen A, Christensen HC, Johansen C, Salminen T, Tynes T, Feychting M (2004) Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer 108:450–455PubMedCrossRefGoogle Scholar
  9. 9.
    Hoffman S, Propp JM, McCarthy BJ (2006) Temporal trends in incidence of primary brain tumors in the United States, 1985–1999. Neuro Oncol 8:27–37PubMedCrossRefGoogle Scholar
  10. 10.
    Hess KR, Broglio KR, Bondy ML (2004) Adult glioma incidence trends in the United States, 1977–2000. Cancer 101:2293–2299PubMedCrossRefGoogle Scholar
  11. 11.
    Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, Linet MS (1999) Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91:1382–1390PubMedCrossRefGoogle Scholar
  12. 12.
    Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267–2276PubMedCrossRefGoogle Scholar
  13. 13.
    Laws ER Jr, Taylor WF, Clifton MB, Okazaki H (1984) Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 61:665–673PubMedGoogle Scholar
  14. 14.
    Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, MacDonald D, Stitt L, Cairncross JG (1999) Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45:923–929PubMedGoogle Scholar
  15. 15.
    North CA, North RB, Epstein JA, Piantadosi S, Wharam MD (1990) Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer 66:6–14PubMedCrossRefGoogle Scholar
  16. 16.
    Shibamoto Y, Kitakabu Y, Takahashi M, Yamashita J, Oda Y, Kikuchi H, Abe M (1993) Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer 72:190–195PubMedCrossRefGoogle Scholar
  17. 17.
    Shaw EG, Daumas-Duport C, Scheithauer BW, Gilbertson DT, O’Fallon JR, Earle JD, Laws ER Jr, Okazaki H (1989) Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 70:853–861PubMedGoogle Scholar
  18. 18.
    Medbery CA III, Straus KL, Steinberg SM, Cotelingam JD, Fisher WS (1988) Low-grade astrocytomas: treatment results and prognostic variables. Int J Radiat Oncol Biol Phys 15:837–841PubMedGoogle Scholar
  19. 19.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO Classification of Tumours of the Central Nervous System. IARC, LyonGoogle Scholar
  20. 20.
    Rius C, Perez G, Martinez JM, Bares M, Schiaffino A, Gispert R, Fernandez E (2004) An adaptation of Charlson comorbidity index predicted subsequent mortality in a health survey. J Clin Epidemiol 57:403–408PubMedCrossRefGoogle Scholar
  21. 21.
    Buntinx F, Niclaes L, Suetens C, Jans B, Mertens R, Van den Akker M (2002) Evaluation of Charlson’s comorbidity index in elderly living in nursing homes. J Clin Epidemiol 55:1144–1147PubMedCrossRefGoogle Scholar
  22. 22.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRefGoogle Scholar
  23. 23.
    Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084PubMedCrossRefGoogle Scholar
  24. 24.
    Collett D (1994) Modelling survival data in medical research. Chapman & Hall, LondonGoogle Scholar
  25. 25.
    Radhakrishnan K, Mokri B, Parisi JE, O’Fallon WM, Sunku J, Kurland LT (1995) The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol 37:67–73PubMedCrossRefGoogle Scholar
  26. 26.
    Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG (2001) Trends in incidence of primary brain tumors in the United States, 1985–1994. Neuro Oncol 3:141–151PubMedCrossRefGoogle Scholar
  27. 27.
    McLendon RE (2006) Errors in surgical neuropathology and the influence of cognitive biases: the psychology of intelligence analysis. Arch Pathol Lab Med 130:613–616PubMedGoogle Scholar
  28. 28.
    Castillo MS, Davis FG, Surawicz T, Bruner JM, Bigner S, Coons S, Bigner DD (2004) Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. Neuroepidemiology 23:85–93PubMedCrossRefGoogle Scholar
  29. 29.
    National Center for Health Statistics (2007), Chartbook on Trends in Health of Americans, Hyatsville, MD.
  30. 30.
    Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A, Gardiman M, Scienza R, Monfardini S, Ermani M (2003) A prospective study on glioblastoma in the elderly. Cancer 97:657–662PubMedCrossRefGoogle Scholar
  31. 31.
    McGirt MJ, Villavicencio AT, Bulsara KR, Friedman AH (2003) MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen. Surg Neurol 59:277–281 discussion 281–272PubMedCrossRefGoogle Scholar
  32. 32.
    Feiden W, Steude U, Bise K, Gundisch O (1991) Accuracy of stereotactic brain tumor biopsy: comparison of the histologic findings in biopsy cylinders and resected tumor tissue. Neurosurg Rev 14:51–56PubMedGoogle Scholar
  33. 33.
    Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncol 3:193–200PubMedCrossRefGoogle Scholar
  34. 34.
    Schiff D, Brown PD, Giannini C (2007) Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 69:1366–1373PubMedCrossRefGoogle Scholar
  35. 35.
    Coons SW, Johnson PC, Pearl DK (1997) The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 41:878–884 discussion 884–875PubMedCrossRefGoogle Scholar
  36. 36.
    Shaffrey ME, Farace E, Schiff D, Larner JM, Mut M, Lopes MB (2005) The Ki-67 labeling index as a prognostic factor in Grade II oligoastrocytomas. J Neurosurg 102:1033–1039PubMedGoogle Scholar
  37. 37.
    Coons SW, Johnson PC (1993) Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 52:609–618PubMedCrossRefGoogle Scholar
  38. 38.
    Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117–1124PubMedGoogle Scholar
  39. 39.
    Chozick BS, Pezzullo JC, Epstein MH, Finch PW (1994) Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35:831–837 discussion 837–838PubMedCrossRefGoogle Scholar
  40. 40.
    Stander M, Peraud A, Leroch B, Kreth FW (2004) Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 101:1028–1035PubMedCrossRefGoogle Scholar
  41. 41.
    Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861PubMedCrossRefGoogle Scholar
  42. 42.
    Jeuken JW, von Deimling A, Wesseling P (2004) Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 70:161–181PubMedCrossRefGoogle Scholar
  43. 43.
    Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126PubMedGoogle Scholar
  44. 44.
    van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990PubMedCrossRefGoogle Scholar
  45. 45.
    Keles GE, Lamborn KR, Berger MS (2001) Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95:735–745PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Nader Pouratian
    • 1
    Email author
  • Melike Mut
    • 1
  • Jay Jagannathan
    • 1
  • M. Beatriz Lopes
    • 2
  • Mark E. Shaffrey
    • 1
  • David Schiff
    • 1
    • 3
    • 4
  1. 1.Department of Neurological SurgeryUniversity of VirginiaCharlottesvilleUSA
  2. 2.Department of Pathology, Division of NeuropathologyUniversity of VirginiaCharlottesvilleUSA
  3. 3.Department of NeurologyUniversity of VirginiaCharlottesvilleUSA
  4. 4.Department of Medicine (Hematology/Oncology)University of VirginiaCharlottesvilleUSA

Personalised recommendations